secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2024-12-06T23:59:59+00:00
Accession:  0001437749-24-036876
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Zevra Therapeutics Announces Departure of Chief Development Officer and Chief Scientific Officer
--------------------------------------------------------------------------------

- Christal Mickle, Chief Development Officer and Co-Founder, notified of departure effective Dec. 6, 2024.
- Sven Guenther, Ph.D., Chief Scientific Officer, departing Zevra effective Dec. 23, 2024.
- Development and scientific functions consolidated under Chief Medical Officer Adrian Quartel, M.D.
- In-house drug discovery discontinued; laboratory facilities in Iowa and Virginia to close.
- Changes include elimination of positions in CMC and Clinical Development as part of strategic plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924036876/0001437749-24-036876-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774924036876/zvra20241204_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-036876

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer